Retatrutide in Research: The Triple Agonist Frontier
Retatrutide (LY3437943) is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors. It represents the next wave of metabolic peptide research after single-pathway GLP-1 drugs and dual incretin agents such as tirzepatide.
For laboratories mapping energy expenditure, liver fat, and body composition endpoints, retatrutide is a priority reference compound. This article is educational and research-focused only — not medical guidance.
Why Three Receptors?
Each pathway contributes distinct physiology:
| Receptor | Research relevance |
|---|---|
| GLP-1 | Insulin secretion, gastric emptying, satiety |
| GIP | Insulinotropic and adipose signalling (context-dependent) |
| Glucagon | Energy expenditure, hepatic lipid metabolism |
Combined activation aims for greater weight loss and metabolic remodelling than GLP-1 alone, with ongoing work to characterise safety and tolerability in human trials.
NZ metabolic programmes often anchor dose arms to Retatrutide 10mg (10 vials) for consistency with published phase-2 dosing discussions.
Reported Research Directions
Early and phase-2 data (subject to peer review and protocol design) explore:
- Mean weight reduction exceeding many GLP-1-only comparators at higher doses
- Waist circumference and body-composition changes via DEXA/MRI substudies
- Glycaemic markers in obesity with and without type 2 diabetes
- Hepatic fat reduction in MASLD-focused cohorts
Animal models use retatrutide to probe brown adipose tissue, lipolysis, and hepatic VLDL pathways that glucagon receptor engagement may amplify.
Dose Strengths for Study Design
Retatrutide programmes span a wide mg range. Kiwi Biolabs lists multiple vial strengths so labs can match institutional calculators without off-label clinical dosing:
| Vial strength | Typical research use |
|---|---|
| 2mg | Pilot PK/PD and tolerability screens |
| 5mg | Mid-range dose arms |
| 10mg | Common reference for multi-week studies |
| 20mg+ | High-dose arms per approved ethics |
Combination boxes such as Retatrutide 5mg + Cagrilintide 5mg support amylin synergy experiments parallel to semaglutide combination lines.
Retatrutide vs Tirzepatide vs Semaglutide
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Targets | GLP-1 | GIP + GLP-1 | GLP-1 + GIP + glucagon |
| Research role | Benchmark | Dual incretin comparator | Triple agonist explorer |
When designing a New Zealand study with three arms, sourcing all comparators from one domestic supplier reduces lot-to-lot shipping variables. See also our articles on semaglutide and tirzepatide.
Sourcing for New Zealand Labs
Kiwi Biolabs provides:
- Janoshik-verified purity on peptide batches
- NZD pricing and NZ-wide discreet shipping
- Labelled 10-vial research boxes aligned with catalogue SKUs
Request CoA when preparing ethics submissions that require third-party analytics.
Summary
Retatrutide pushes metabolic peptide research into triple-pathway territory. For Kiwi laboratories, retatrutide 10mg reference vials from kiwibiolab.com support reproducible comparator studies alongside established GLP-1 and dual agonists.
Disclaimer: For laboratory and research use only. Not for human consumption. Retatrutide is investigational; comply with all applicable regulations.